February 03, 2011 at 12:21 PM EST
(OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration
Orexigen Therapeutics Inc. (OREX) was dealt a severe blow by the US Food and Drug Administration (FDA) when the regulatory body declined to approve its obesity drug, Contrave in the present form and issued a complete response letter (CRL). Contrave, which aimed at addressing the physiological and behavioral causes of obesity, has been co-developed with [...] (OREX) Orexigen Therapeutics Gets Severe Setback from US Food and Drug Administration
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here